While Harvard Bioscience Inc. has overperformed by 0.95%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HBIO rose by 13.07%, with highs and lows ranging from $6.29 to $3.26, whereas the simple moving average fell by -8.39% in the last 200 days.
On March 10, 2023, The Benchmark Company Upgraded Harvard Bioscience Inc. (NASDAQ: HBIO) to Buy. A report published by The Benchmark Company on January 07, 2021, Upgraded its rating to ‘Buy’ for HBIO. Northland Capital also rated HBIO shares as ‘Outperform’, setting a target price of $6 on the company’s shares in an initiating report dated December 09, 2020. KeyBanc Capital Markets Initiated an Overweight rating on November 10, 2020, and assigned a price target of $6. Janney July 08, 2019d its ‘Buy’ rating to ‘Neutral’ for HBIO, as published in its report on July 08, 2019. Janney’s report from January 24, 2018 suggests a price prediction of $8 for HBIO shares, giving the stock a ‘Buy’ rating. The Benchmark Company also rated the stock as ‘Buy’.
Analysis of Harvard Bioscience Inc. (HBIO)
Further, the quarter-over-quarter decrease in sales is -0.96%, showing a negative trend in the upcoming months.
To gain a thorough understanding of Harvard Bioscience Inc.’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -4.70% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 0.92, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and HBIO is recording an average volume of 84.38K. On a monthly basis, the volatility of the stock is set at 6.30%, whereas on a weekly basis, it is put at 5.50%, with a loss of -2.75% over the past seven days. Furthermore, long-term investors anticipate a median target price of $6.92, showing growth from the present price of $4.24, which can serve as yet another indication of whether HBIO is worth investing in or should be passed over.
How Do You Analyze Harvard Bioscience Inc. Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 7.77%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 76.69% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
HBIO shares are owned by institutional investors to the tune of 76.69% at present.
